AUROPHARMA

Aurobindo Pharma is an interesting pharma stock because the fundamentals have improved sharply in FY27, but the stock is also facing an important technical resistance zone and a fresh USFDA development today. 1. Company Overview Aurobindo Pharma is one of India's major pharmaceutical companies, with a strong presence in generic formulations, APIs and injectable products. The US remains an important market for the company, making regulatory approvals and USFDA observations important stock-price triggers. 2. Fundamental Analysis Q1 FY27 was strong Aurobindo Pharma reported: Parameter Q1 FY27 YoY Revenue from Operations ₹9,150 Cr +16.3% PAT ₹1,032 Cr +25.2% EBITDA Margin 20.56% Improved Q4 FY26 Revenue ₹8,853 Cr +3.35% QoQ Revenue growth of 16.3% accompanied by 25.2% profit growth indicates operating leverage and margin improvement. Why the numbers are encouraging 1. Profit is growing faster than revenue Revenue +16%, while PAT +25%. This is a positive sign because earnings are expanding faster than the top line. 2. EBITDA margin around 20.6% The company has maintained a strong margin profile. For comparison, Q3 FY26 EBITDA margin was around 20.5%. 3. Long-term earnings trajectory has improved The company's financial highlights show a substantial improvement in EBITDA over the longer term, supporting the argument that this isn't merely a one-quarter story.